CD274 and neoplasm: Two cases of UCOGC that were treated successfully with anti-PD-L1 drugs were recently described; in one case, pembrolizumab therapy was administered due to positive PD-L1 immunohistochemistry [40], and in another case, due to high tumor mutational burden (TMB) [41].